NCT02215720 2026-03-20
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
Clinical Trials
13 trialsNCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT01596140 2020-06-04
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00909831 2019-04-16
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00770263 2015-06-03
Erlotinib and Temsirolimus for Solid Tumors
Washington University School of Medicine
Phase 1 Completed
NCT02446431 2015-05-18
Metronomic
Miller Children's & Women's Hospital Long Beach
Phase EARLY_PHASE1 Recruiting
NCT00255658 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00788580 2015-03-06
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00880282 2014-04-29
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
National Cancer Institute (NCI)
Phase 1 Completed
NCT01141244 2014-04-10
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01050985 2014-02-13
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Georgetown University
Phase 1 Completed
NCT00098501 2013-06-04
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01072890 2012-03-28
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
University of California, Davis
Phase 1 Completed